| 07/01/22 | Delisting of AS "Olainfarm” shares from the Baltic Main list | AQ |
| 06/01/22 | Notification about results of final buy-back of shares | AQ |
| 30/12/21 | Notification about final share buy-back | AQ |
| 28/12/21 | Correction: Regarding results of a share buy-back offer | AQ |
| 28/12/21 | On substantial participation (4) - specified | AQ |
| 1 day | -0.24% |
| Manager | Title | Age | Since |
|---|---|---|---|
Juris Hmelnickis
CEO | Chief Executive Officer | 46 | 01/01/2026 |
Janis Leimanis
DFI | Director of Finance/CFO | 56 | - |
| Chief Tech/Sci/R&D Officer | - | 01/01/2010 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 63 | 19/06/2021 | |
Janis Buks
CHM | Chairman | - | 01/09/2022 |
Roberts Tavjevs
BRD | Director/Board Member | - | - |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.24% | -3.46% | - | - | 148M | |
| +0.56% | +2.41% | +15.42% | +75.01% | 49.85B | |
| -1.74% | +3.57% | +56.23% | +116.36% | 36.89B | |
| -0.54% | +5.27% | -5.96% | +24.80% | 12.43B | |
| -0.68% | +0.12% | +12.05% | +76.37% | 11.69B | |
| +1.05% | +0.96% | +31.25% | +132.30% | 9.04B | |
| -1.36% | +2.46% | +47.46% | -5.54% | 7.15B | |
| +0.34% | +0.77% | +13.87% | +32.21% | 6.7B | |
| -3.16% | -0.67% | +1.70% | +178.01% | 6.66B | |
| +0.61% | -3.87% | -35.09% | -1.66% | 5.45B | |
| Average | -0.52% | +1.38% | +15.22% | +69.76% | 16.21B | |
| Weighted average by Cap. | -0.46% | +2.51% | +23.62% | +80.78% |
Employees
2,191
Sector
Pharmaceuticals
